Clinical trials: Prostate-Specific Antigen
Suspected Primary Prostate Cancer
Evaluation of a Transrectal Scintigraphic Detector(ProxiScanTM) for Detection of Primary Prostate Cancer
This is a feasibility, exploratory, and proof-of-concept study to evaluate rectal probe scintigraphy device (ProxiScanTM) to detect PSMA specific radiopharmaceutical agent (ProstaScint®) in patients with suspected primary…
- Trial name
- NCT01359189
- Testing
- ProxiScan (scintigraphic rectal probe)
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer
GTx-758 on Serum Prostate-specific Antigen (PSA) in Men With Castrate Resistant Prostate Cancer
The purpose of this study is to assess the effect of GTx-758 on Serum Prostate-specific antigen (PSA) levels in men with castrate resistant prostate cancer who are maintained on androgen deprivation therapy (Serum PSA response…
- Trial name
- NCT01420861
- Testing
- GTx-758
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- GTx
Prostate Infections
Impact of Antibiotic Treatment on Prostate-Specific Antigen (PSA) Variability
Ciprofloxacin hydrochloride has been approved by the Food and Drug Administration (FDA) for the treatment of mild to moderate infections, including prostate infections.
- Trial name
- NCT00596453
- Testing
- Ciprofloxacin hydrochloride
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Johns Hopkins University
Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors
A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors
This is a Phase 1b/Phase 2a, open-label, multicenter study to determine the safety, tolerability, recommended Phase 2 dose (RP2D), efficacy, pharmacokinetics (PK) and pharmacodynamic (PD) properties of idronoxil when rectally…
- Trial name
- NCT04957290
- Testing
- NOX66, EBRT
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Noxopharm Limited
Prostatic Neoplasms
Imperial Prostate 6 - Cancer Histology Artificial Intelligence Reliability Study.
The primary objective is to determine whether the Galen Prostate AI system has sufficient diagnostic accuracy and health economic value to be used for triage of pathology slides within the NHS.
- Trial name
- IP6-CHAIROS (NCT05228197)
- Testing
- Biopsy & Imaging
- Where
- 6 sites in United Kingdom
- Volunteers
- 750 people
- Sponsor
- Imperial College London
Prostate Cancer, Prostate Cancer, Familial
Clinical Validity and Utility of Genomic-targeted Chemoprevention of PCa: Aim 4a
This study was designed to compare the efficacy, perception, decision making, and cost-effectiveness of genomic and non-genomic approaches for risk assessment of prostate cancer and for chemoprevention of prostate cancer.
- Conditions
- Prostate Cancer, Prostate Cancer, Familial, Hereditary Prostate Cancer
- Trial name
- NCT02381015
- Testing
- Genetic Risk Score: Number Format, Genetic Risk Score: Number + Pictograph, Family History: Number Format
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Endeavor Health
Prostate Cancer
Follow-Up Study for Men Diagnosed With Prostate Cancer Through Participation in a Prostate Specific Antigen Screening Program
There is controversy concerning the preferred treatment for men with localized prostate cancer with regard to the relative effectiveness of different treatments in controlling the cancer and how different treatments affect the…
- Trial name
- NCT00035217
- Where
- United States
- Sponsor
- National Center for Research Resources (NCRR)
Prostate Cancer
Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC
The purpose of this trial is to learn more about the effects of AAA602 and AAA802 in men with prostate-specific membrane antigen (PSMA) positive high-risk localized prostate cancer (HRLPC) before surgery to remove the prostate…
- Trial name
- NeoPSMA (NCT06881823)
- Testing
- AAA602, AAA802, Gallium (68Ga) gozetotide
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens.
- Trial name
- NCT00003653
- Testing
- bicalutamide, buserelin, cyproterone acetate
- Where
- 29 sites in Canada
- Volunteers
- 1,386 people
- Sponsor
- NCIC Clinical Trials Group
Prostate Cancer
68Ga-RM2 Compared to 68Ga-PSMA-617 PET/CT for Intermediate Risk Prostate Cancer Imaging
Patients with primary intermediate risk prostate cancer for whom radical prostatectomy is indicated, will be invited to participate to the present study.
- Trial name
- PROSTATEP (NCT03606837)
- Testing
- 68Ga-PSMA-617 PET/CT, 68Ga-RM2 PET/CT
- Where
- France
- Volunteers
- 14 people
- Sponsor
- University Hospital, Bordeaux
Localized Prostate Carcinoma, Prostate Adenocarcinoma
Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland
Apalutamide is an anti-androgen that blocks the effect of testosterone on prostate cancer growth. This phase IIa trial is designed to determine whether very low doses of apalutamide, given for 3 to 4 weeks before prostate surgery…
- Conditions
- Localized Prostate Carcinoma, Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8
- Trial name
- NCT04530552
- Testing
- Apalutamide, Biospecimen Collection, Quality-of-Life Assessment
- Where
- 5 sites in United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Disease, Elevated Prostate Specific Antigen
MR/TRUS Fusion Guided Prostate Biopsy
This study will determine if targeted (Magnetic Resonance (MR) / Ultrasound (US) fusion biopsy) plus conventional biopsy is superior to conventional biopsy alone in diagnosing subjects with prostate cancer.
- Conditions
- Prostate Disease, Elevated Prostate Specific Antigen, Family History of Prostate Cancer, Positive Digital Rectal Exam
- Trial name
- NCT04026763
- Testing
- prostate biopsy, MR US Fusion Guided Prostate Biopsy, MR/TRUS Fusion Guided Prostate Biopsy
- Where
- United States
- Volunteers
- 520 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Prostatic Neoplasms
Study of a 6-Month Sustained-Release Formulation of Leuprolide Acetate in Prostate Cancer
The primary purpose of the study is to determine if a new sustained-release 45 mg (depot) formulation of leuprolide acetate will reduce serum testosterone levels to and maintain them at medically castrate levels in subjects with…
- Trial name
- NCT00056654
- Testing
- Leuprolide acetate
- Where
- 55 sites in United States
- Volunteers
- 164 people
- Sponsor
- Abbott
Elevated Prostate Specific Antigen
Randomized Trial of Ciprofloxacin Versus Observation for Men With Elevated Prostate Specific Antigen (PSA)
The purpose of this study is to assess the impact of an empiric course of antibiotics for men with an elevated prostate-specific antigen (PSA) level.
- Trial name
- NCT00840294
- Testing
- Ciprofloxacin
- Where
- United States
- Volunteers
- 85 people
- Sponsor
- University of Chicago
Prostatic Neoplasms
Effect of Modified Citrus Pectin on PSA Kinetics in Biochemical Relapsed PC With Serial Increases in PSA
To determine if the oral administration of PectaSol-C Modified Citrus Pectin (MCP) is effective at improving Prostate Specific Antigen (PSA) kinetics in men with biochemical relapsed prostate cancer and serial increases in PSA…
- Trial name
- NCT01681823
- Testing
- PectaSol-C Modified Citrus Pectin (MCP)
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- EcoNugenics
Prostatic Neoplasms
The Application Value of Prostate Specific Membrane Antigen PET/CT in Biopsy Free of PSA Grey Area Prostate Cancer
The goal of this observational study is to establish an evaluation system for accurate identification of prostate cancer and clinical significant prostate cancer in patients in the PSA gray zone.
- Trial name
- NCT05958004
- Where
- China
- Volunteers
- 92 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer
This phase II trial is studying how well vaccine therapy works in treating patients with recurrent prostate cancer. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells
- Trial name
- NCT00109811
- Testing
- PSA:154-163(155L) peptide vaccine, incomplete Freund's adjuvant, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute (NCI)
Prostatic Neoplasm
A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC
The purpose of this study is to evaluate the efficacy and safety of AAA617 alone (Lutetium [177Lu] vipivotide tetraxetan) and in combination with an Androgen Receptor Pathway Inhibitors (ARPI) in participants with PSMA-positive…
- Trial name
- PSMACare (NCT05849298)
- Testing
- AAA617, AAA517, Piflufolastat F 18
- Where
- 31 sites in United States, Brazil and 9 more
- Volunteers
- 49 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Carcinoma
Study of Metformin With Simvastatin for Men With Prostate Carcinoma
The purpose of this study is to find out whether the two drugs used in the study, metformin and simvastatin, can slow down the speed of rise of prostate specific antigen (PSA) or stop its rise or even bring the level down.
- Trial name
- NCT01561482
- Testing
- Metformin, Simvastatin
- Where
- 3 sites in United States
- Sponsor
- Nicholas Mitsiades
Localized Prostate Cancer
18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy
Background: Identifying medium- and high-risk prostate cancer early may allow for treatments to work. But identification can be hard. Researchers want to see if a radiotracer used during PET scans can help.
- Trial name
- NCT05155046
- Testing
- 18F-DCFPyL
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- National Cancer Institute (NCI)